MilliporeSigma has closed its purchase of Exelead, a biopharmaceutical contract development and manufacturing services firm that has developed lipid nanoparticle (LNP)-based drug delivery technology.
MilliporeSigma plans to invest more than $565 million over the next 10 years to further expand Exelead's PEGylated research and development and its LNP-based drug delivery technology, which is key to mRNA vaccines and therapeutics, MilliporeSigma said.
The company believes that Exelead will complement the experience it already has in its life sciences sector in producing lipids, in addition to expertise in mRNA manufacturing that MilliporeSigma acquired through its purchase of AmpTec in 2020.
MilliporeSigma is the U.S. and Canadian life science business of Merck KGaA of Darmstadt, Germany.
